EligibleTrials

Clinical trials recruiting for Borderline Resectable Pancreatic Adenocarcinoma

6
Recruiting trials
6
US states with sites
6
Countries
0%
Accept healthy volunteers

Phase breakdown

Phase 1 2Phase 2 3Not applicable 2

Drugs and treatments being studied

InterventionTrials
Folfirinox1
HRS-4642+AG+Nimotuzumab1
Isotoxic High-Dose (iHD)-SBRT1
PTM-1011
Pembrolizumab1
SABR1
Standard Reagents, Pancreatic Cancer1
mFOLFIRINOX or Gemcitabine nab-paclitaxel1

Where trials are recruiting (top US states)

StateRecruiting trials
California1
Florida1
Michigan1
New York1
Texas1
Washington1

Top cities

Dallas, Texas 1Detroit, Michigan 1Houston, Texas 1Lake Success, New York 1Miami, Florida 1Newport Beach, California 1Seattle, Washington 1

Self-screener

Recruiting trials

Related conditions

Trials recruiting for Borderline Resectable Pancreatic Adenocarcinoma often also study these conditions. Each links to its own recruiting-trial list.

Pancreatic cancer 870Resectable Pancreatic Adenocarcinoma 5Locally Advanced Pancreatic Adenocarcinoma 16Pancreatic Neoplasm 17Pancreatic Ductal Adenocarcinoma 64Pancreatic Adenocarcinoma 49Pancreas Neoplasm 8Pancreas Disease 5Pancreas Cancer 86Pancreas Adenocarcinoma 19

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Borderline Resectable Pancreatic Adenocarcinoma trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.